Whiting P J, Vincent A, Newsom-Davis J
Neurology. 1986 May;36(5):612-7. doi: 10.1212/wnl.36.5.612.
We investigated the heterogeneity of serum antibodies to acetylcholine receptor (AChR) by competition with nine antihuman monoclonal antibodies in a cross-sectional study of 36 patients with myasthenia gravis (MG), and in three who showed clinical improvement associated with decrease in total anti-AChR following immunologic treatment. Two specificities were more prevalent in patients without thymoma, an done of these was more prevalent in cases beginning before age 40. Some specificities were stable during serial studies, whereas other fluctuated. We found evidence of three groups of antibody specificities that had different control mechanisms and may define different regions of the receptor.
在一项对36例重症肌无力（MG）患者以及3例在免疫治疗后临床症状改善且总抗乙酰胆碱受体（AChR）抗体水平降低的患者的横断面研究中，我们通过与9种抗人单克隆抗体竞争，研究了血清抗AChR抗体的异质性。两种特异性在无胸腺瘤的患者中更为普遍，其中一种在40岁之前起病的病例中更为常见。一些特异性在系列研究中保持稳定，而其他的则有波动。我们发现有证据表明存在三组抗体特异性，它们具有不同的调控机制，可能界定了受体的不同区域。
